nutrients-logo

Journal Browser

Journal Browser

Relevance between Lipid Metabolism, Nutrition and Chronic Disease

A special issue of Nutrients (ISSN 2072-6643). This special issue belongs to the section "Lipids".

Deadline for manuscript submissions: closed (5 June 2024) | Viewed by 1770

Special Issue Editor


E-Mail Website
Guest Editor
Clinical Institute for Medical and Chemical Diagnostics, Medical University of Graz, Graz, Austria
Interests: obesity; adipose tissue distribution; metabolic syndrome; non-alcoholic fatty liver disease; dyslipidemia; inflammation; immune dysfunction
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue will address new basic and clinical research data of obesity- and dyslipidemia-related pathologic sequelae as well as nutritional strategies. Obesity and dyslipidemia are responsible for the increasing burden of chronic diseases in the industrialized world. Sessile lifestyle, ingestion of highly processed food, and individual genetic risk constellations contribute to cardiovascular, hepatic, cerebrovascular, and oncologic diseases, all of which are detrimental for a healthy life. A better understanding of the underlying mechanisms is important. The COVID-19 pandemic has indeed shown that metabolic and immunologic dysfunction associated with obesity and diabetes mellitus essentially contributes to fatal courses of COVID-19. This Issue cordially invites all researchers working with such pathologic sequelae of obesity and the relevance between nutrition intaking to submit reviews and original research manuscripts to this topic.

Prof. Dr. Harald Mangge
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • obesity
  • adipose tissue distribution
  • insulin resistance
  • non-alcoholic fatty liver disease
  • subcutaneous, intermuscular, visceral, and pericardial adipose tissue

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 1096 KiB  
Article
Effects of Xanthine Oxidase Inhibition by Febuxostat on Lipid Profiles of Patients with Hyperuricemia: Insights from Randomized PRIZE Study
by Yuichi Saito, Atsushi Tanaka, Hisako Yoshida, Hitoshi Nakashima, Noriko Ban, Munehide Matsuhisa, Yoshio Kobayashi, Koichi Node and on behalf of the PRIZE Study Investigators
Nutrients 2024, 16(14), 2324; https://doi.org/10.3390/nu16142324 - 19 Jul 2024
Cited by 1 | Viewed by 1422
Abstract
Although patients with hyperuricemia and gout often have dyslipidemia, the effects of febuxostat, a xanthine oxidase inhibitor, on their lipid profiles are unclear. Thus, we performed a sub-analysis of the randomized PRIZE study in which the effects of febuxostat on carotid atherosclerosis were [...] Read more.
Although patients with hyperuricemia and gout often have dyslipidemia, the effects of febuxostat, a xanthine oxidase inhibitor, on their lipid profiles are unclear. Thus, we performed a sub-analysis of the randomized PRIZE study in which the effects of febuxostat on carotid atherosclerosis were investigated in patients with hyperuricemia. The participants were randomized to the febuxostat or control group. The primary endpoint of this sub-analysis was changes in the patients’ non-high-density lipoprotein cholesterol (HDL-C) levels from baseline to 6-month follow-up. Correlations between the changes in lipid profiles and cardiometabolic parameters were also evaluated. In total, 456 patients were included. From baseline to 6 months, non-HDL-C levels were significantly reduced in the febuxostat group (−5.9 mg/dL, 95% confidence interval [CI]: −9.1 to −2.8 mg/dL, p < 0.001), but not in the control group (−1.3 mg/dL, 95% CI: −4.4 to 1.8, p = 0.348). The reduction in non-HDL-C levels was more pronounced in women and correlated with changes in serum uric acid and estimated glomerular filtration rate levels only in the febuxostat group. In patients with hyperuricemia, febuxostat treatment was associated with reduced non-HDL-C levels from baseline to the 6-month follow-up compared to the control treatment, suggesting that the lipid-lowering effect of febuxostat should be considered when targeting dyslipidemia. Full article
(This article belongs to the Special Issue Relevance between Lipid Metabolism, Nutrition and Chronic Disease)
Show Figures

Figure 1

Back to TopTop